Impact of age at diagnosis of de novo metastatic prostate cancer on survival
Author:
Affiliation:
1. Dana‐Farber Cancer Institute Boston Massachusetts
2. Boston University School of Public Health Boston Massachusetts
3. Princess Margaret Cancer Centre Toronto Ontario Canada
Publisher
Wiley
Subject
Cancer Research,Oncology
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.32630
Reference34 articles.
1. National Cancer Institute.Cancer Stat Facts: Prostate Cancer. Accessed September 25 2018.http://seer.cancer.gov/statfacts/html/prost.html
2. Cancer statistics, 2019
3. Annual Report to the Nation on the Status of Cancer, part II: Recent changes in prostate cancer trends and disease characteristics
4. No improvement noted in overall or cause-specific survival for men presenting with metastatic prostate cancer over a 20-year period
5. Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial
Cited by 36 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Comparison of Short-Term Outcomes and Safety Profiles between Androgen Deprivation Therapy+Abiraterone/Prednisone and Androgen Deprivation Therapy+Docetaxel in Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer;The World Journal of Men's Health;2024
2. Efectos de la privación androgénica en cáncer de próstata de alto riesgo en ancianos: estudio observacional PROSARC;Actas Urológicas Españolas;2024-01
3. Real-world progression in the survival of de novo Metastatic prostate cancer over the past decade;Urologic Oncology: Seminars and Original Investigations;2023-12
4. Clinical Outcomes of Enzalutamide in Metastatic Hormone-sensitive Prostate Cancer in Patients Aged <75 and ≥75 Years: ARCHES Post Hoc Analysis;European Urology Oncology;2023-12
5. Differences in overall survival of penile cancer patients versus population‐based controls;International Journal of Urology;2023-11-28
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3